Sutro Biopharma doses first patient in Phase 1 trial of STRO-006 ADC
Tweet Send to a Friend
Sutro Biopharma (NASDAQ: STRO) announced that the first patient has been dosed in a Phase 1 trial of STRO-006, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




